Ernexa Therapeutics Inc.

The company is a preclinical-stage company focused on synthetic allogeneic iMSC therapy. iMSCs are mesenchymal stem cells derived from induced pluripotent stem cells. The company aims to develop scalable, affordable, off-the-shelf cell therapies for cancer and autoimmune disease. Its lead product candidate, ERNA-101, consists of allogeneic IL-7 and IL-15-secreting iMSCs. ERNA-101 is designed to target tumors and deliver pro-inflammatory factors directly to the tumor microenvironment, potentially enhancing T-cell anti-tumor activity while limiting systemic exposure and toxicity. The initial development focus for ERNA-101 is platinum-resistant ovarian cancer. In a preclinical study with the University of Texas MD Anderson Cancer Center, ERNA-101 reduced tumor growth and showed a statistically significant survival advantage in an ovarian cancer model compared to a control group. In the fourth quarter of 2025, the company had a successful pre-Investigational New Drug (IND) meeting with the Food and Drug Administration (FDA). The company is also investigating ERNA-201, which are anti-inflammatory cytokine (e.g., IL-10)-secreting iMSCs, for autoimmune disorders such as rheumatoid arthritis.